+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oral Medications for Multiple Sclerosis Market - Global Forecast 2026-2032- Product Image
Oral Medications for Multiple Sclerosis Market - Global Forecast 2026-2032- Product Image
New

Oral Medications for Multiple Sclerosis Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 193 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6124774
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The oral medications for multiple sclerosis market is evolving rapidly as clinical requirements, payer expectations, and operational considerations change. Senior leaders navigating this sector must address advancing innovation, heightened safety needs, and growing complexity in access and distribution. These shifts create new imperatives for evidence-based decision-making and operational agility in the global landscape.

Market Snapshot: Oral Medications for Multiple Sclerosis Market

The global oral medications for multiple sclerosis market is projected to expand from USD 6.37 billion in 2025 to USD 6.76 billion in 2026, reaching USD 10.44 billion by 2032 with a CAGR of 7.31%. Strategic market growth is fueled by increasing demand for patient-centric therapeutics, regulatory refinement across regions, and the integration of oral solutions in diverse care environments. Expansion is also underpinned by ongoing pressure from patent expiration, a robust and innovative development pipeline, and the influences of unique access frameworks in key geographies.

Scope & Segmentation

  • Disease Subtypes: The market addresses relapsing-remitting MS, secondary progressive MS, and other clinically pertinent forms. Each subtype entails different treatment strategies, requiring tailored approaches to persistence and disease control.
  • Line of Therapy: Therapies are positioned for first-line, second-line, and subsequent uses, with product choice steered by prior adverse events, sequence logistics, and patient history including washout routines.
  • Drug Classes: Segmentation by immunomodulatory mechanisms underlines the diversity in safety considerations, response monitoring, and clinical applicability.
  • Distribution Channels: Distribution spans specialty pharmacies, hospital and clinic dispensaries, and retail channels—each presenting distinct access challenges and implications for adherence support.
  • Patient Demographics: Age, comorbidities, reproductive health, and risk tolerance shape prescribing decisions and long-term management planning, driving customized clinical pathways.
  • Regional Coverage: The Americas, Europe, Middle East & Africa, and Asia-Pacific represent markets with diverse payer systems, regulatory readiness, and infrastructural strengths, influencing development and deployment priorities.
  • Digital Technologies: Remote monitoring, digital reminders, and integrated patient management solutions are increasingly incorporated to promote adherence and monitor safety, emphasizing the need for compatibility with patient privacy and clinician workflow.

Key Takeaways for Senior Decision-Makers

  • Oral MS therapies bring enhanced convenience for patients but require rigorous approaches to ensure daily adherence, manage risk, and enable continuous safety monitoring.
  • Therapy choices center on sequencing and individualization, balancing treatment accessibility with optimal disease management given patient characteristics and existing comorbidities.
  • Entry of generics increases market competition, prompting branded products to rely on differentiated patient services, such as enhanced adherence programs and use of real-world performance data to support continued formulary inclusion.
  • The growing role of specialty pharmacies is shifting operational focus toward improved authorization protocols, patient engagement, and advanced refill management for sustained product use.
  • Digital enablement is facilitating earlier adverse event recognition and improved treatment oversight, though successful solutions minimize additional administrative responsibilities for clinical staff.
  • Regional differences in payer systems, assessment methodologies, care infrastructure, and regulatory adaptation demand tailored approaches to product access and commercialization strategies.

Tariff Impact: Navigating 2025 Supply Chain and Cost Challenges

Anticipated US tariff changes in 2025 are set to impact the oral multiple sclerosis medications landscape by elevating input costs and increasing variability in sourcing. These adjustments place renewed emphasis on supply chain resilience as tariffs on active ingredients, excipients, and packaging can drive procurement volatility and put pressure on margins. Manufacturers are responding through greater supplier diversification, expanding local and nearshore production, and refined risk planning. Generics, in particular, face exposure to fluctuating input costs, influencing their pricing strategies and supply continuity. Payers and policy entities are heightening demands for transparency and compliance in sourcing and system quality.

Methodology & Data Sources

This market analysis employs structured secondary research and cross-disciplinary interviews with neurologists, pharmacists, payers, and supply chain experts. The report triangulates insights across clinical, access, and operational domains, prioritizing validated and actionable intelligence for business leaders.

Why This Report Matters

  • Equips executives to anticipate regulatory, access, and safety developments in established and emerging markets for oral multiple sclerosis medications.
  • Supports data-driven decisions in product positioning, procurement, and payer engagement, with guidance for building more resilient supply networks in tariff-sensitive environments.
  • Delivers actionable analysis on optimizing digital tools and patient services to improve adherence and meet clinical and commercial goals.

Conclusion

Achievement in the oral MS therapies market requires strong evidence-based strategies paired with operational expertise. Organizations that proactively adapt to new access, safety, and regional requirements are positioned to succeed as the sector becomes increasingly complex.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Oral Medications for Multiple Sclerosis Market, by Molecule
8.1. Dimethyl Fumarate
8.2. Diroximel Fumarate
8.3. Fingolimod
8.4. Monomethyl Fumarate
8.5. Ozanimod
8.6. Ponesimod
8.7. Siponimod
8.8. Teriflunomide
9. Oral Medications for Multiple Sclerosis Market, by Drug Class
9.1. Dihydroorotate Dehydrogenase Inhibitors
9.2. Fumarates
9.2.1. Dimethyl Fumarate
9.2.2. Diroximel Fumarate
9.2.3. Monomethyl Fumarate
9.3. Sphingosine 1 Phosphate Receptor Modulators
9.3.1. Fingolimod
9.3.2. Ozanimod
9.3.3. Ponesimod
9.3.4. Siponimod
10. Oral Medications for Multiple Sclerosis Market, by Indication
10.1. Clinically Isolated Syndrome
10.2. Relapsing Remitting Multiple Sclerosis
10.3. Secondary Progressive Multiple Sclerosis Active
11. Oral Medications for Multiple Sclerosis Market, by Line Of Therapy
11.1. First Line
11.2. Later Line
11.3. Second Line
12. Oral Medications for Multiple Sclerosis Market, by Dosage Form
12.1. Capsule
12.2. Tablet
13. Oral Medications for Multiple Sclerosis Market, by Distribution Channel
13.1. Hospital Pharmacy
13.2. Retail Pharmacy
13.3. Specialty Pharmacy
14. Oral Medications for Multiple Sclerosis Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Oral Medications for Multiple Sclerosis Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Oral Medications for Multiple Sclerosis Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Oral Medications for Multiple Sclerosis Market
18. China Oral Medications for Multiple Sclerosis Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. AbbVie Inc.
19.6. Acorda Therapeutics, Inc.
19.7. Bayer AG
19.8. Biogen Inc.
19.9. Bristol-Myers Squibb Company
19.10. Clene Nanomedicine, Inc.
19.11. Eisai Co., Ltd.
19.12. F. Hoffmann-La Roche Ltd.
19.13. GlaxoSmithKline plc
19.14. Immensa Biotherapeutics, Inc.
19.15. Immunic, Inc.
19.16. Janssen Pharmaceuticals, Inc.
19.17. Merck KGaA
19.18. Mitsubishi Tanabe Pharma Corporation
19.19. Novartis AG
19.20. Oryzon Genomics, S.A.
19.21. Pfizer Inc.
19.22. Sanofi
19.23. Teva Pharmaceutical Industries Ltd.
19.24. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TERIFLUNOMIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TERIFLUNOMIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TERIFLUNOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CLINICALLY ISOLATED SYNDROME, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CLINICALLY ISOLATED SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CLINICALLY ISOLATED SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS ACTIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS ACTIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS ACTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LATER LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LATER LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LATER LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 136. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 137. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
TABLE 138. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 139. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 140. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 141. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 142. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 146. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
TABLE 147. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 148. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 152. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 154. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 155. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
TABLE 156. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 157. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 158. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 159. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 160. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 170. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 171. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 173. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 174. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
TABLE 175. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 176. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 177. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 178. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 179. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 182. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 183. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
TABLE 184. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 185. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 186. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 187. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 188. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 198. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 199. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 200. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 201. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
TABLE 202. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 203. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 204. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 205. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 206. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 207. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 209. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 210. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
TABLE 211. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 212. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 213. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 214. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 215. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 216. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 218. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 219. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
TABLE 220. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 221. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 222. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 223. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 224. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 225. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
TABLE 230. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 231. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 232. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 233. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 234. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 235. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 236. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
TABLE 237. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 238. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
TABLE 239. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 240. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 241. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 242. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 243. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Oral Medications for Multiple Sclerosis market report include:
  • AbbVie Inc.
  • Acorda Therapeutics, Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Clene Nanomedicine, Inc.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Immensa Biotherapeutics, Inc.
  • Immunic, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Oryzon Genomics, S.A.
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 6.76 Billion
Forecasted Market Value ( USD ) by 2032 $ 10.44 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Multiple Sclerosis Market - Global Forecast 2026-2032 - Product Image

Multiple Sclerosis Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Relapsing-Remitting Multiple Sclerosis - Market Insights, Epidemiology, and Market Forecast - 2034 - Product Image

Relapsing-Remitting Multiple Sclerosis - Market Insights, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Amyotrophic Lateral Sclerosis Treatment Market - Global Forecast 2026-2032 - Product Image

Amyotrophic Lateral Sclerosis Treatment Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Multiple Sclerosis Therapeutics - Global Strategic Business Report - Product Image

Multiple Sclerosis Therapeutics - Global Strategic Business Report

  • Report
  • 268 Pages
  • Global
From
Multiple Sclerosis Therapies Market Report by Drug, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033 - Product Image

Multiple Sclerosis Therapies Market Report by Drug, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.